ArticleResearch square2025
Multi-trait polygenic risk scores improve genomic prediction of atrial fibrillation across diverse ancestries.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
Abstract
Polygenic scores (PGSs) can improve atrial fibrillation (AF) risk prediction, both alone and alongside clinical scores, offering potential for guiding targeted screening. However, their limited accuracy and cross-ancestry transferability remain major barriers to clinical translation. Here, we explored several multi-PGS approaches to generate ancestry-optimized PGSs for AF, and tested these in independent samples from the All of Us Research Program. Our ancestry-specific multi-trait approach, which leverages correlated traits, in particular outperformed the current gold-standard PGS among Asian (OR/SD = 1.76 [1.56-1.99]; AUROC = 0.637; AUPRC = 0.055), Admixed American (1.45 [1.38-1.53]; 0.595; 0.054) and African ancestry groups (1.39 [1.32-1.45]; 0.573; 0.064). Although predictive accuracy remained highest among Europeans (1.89 [1.85-1.93]; 0.646; 0.157) - in whom our PGS explained ~ 50% of SNP-heritability - our multi-trait approach yielded relatively larger gains in non-European populations. Improved risk stratification was also observed at PGS extremes, identifying a substantial proportion of European individuals with risk comparable to rare
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.